ERBB2 and cancer: Luen et al. have evaluated the genomic driver alteration associated with distant recurrences ≥5 years in postmenopausal HR+/HER2- breast cancers.25 They found that those with 8p11 and BRCA2 mutations had a higher risk of late distant recurrence compared to wild-type cancers.